ANA President Jennifer Mensik Kennedy outlines systemic nurse fatigue mitigation policies, emphasizing patient safety and acuity across oncology care.
|Articles|May 26, 2011
Donna Berry on the Implications of Oral Oncolytics
Author(s)Donna Berry, PhD, RN
Donna Berry from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the Implications of Oral Oncolytics
Advertisement
Donna Berry, PhD, RN, AOCN®, FAAN, from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the implications of oral oncolytics as observed in her research on patient adherence to oral oncolytic therapy, symptom management, patient quality of life, and patient decision making in cancer treatment.
Advertisement
Related to this article
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
The FDA has approved oral iberdomide (Zenbexus) for relapsed/refractory multiple myeloma, offering patients a highly potent, accessible therapy.
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
With daraxonrasib approved for metastatic pancreatic cancer, Yolanda Justal, APRN, discusses essential nursing workflows for home-based care.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Reframing Nurse Fatigue as Systemic Safety Risk
2
Oncology Nurse Shares Insights From Her Stage 4 Breast Cancer Journey
3
Psychedelic Medicine in Cancer Care: What Nursing Teams Need to Know
4
FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma
5